Sygen Pharmaceuticals, ORx Pharmaceuticals Form Sygen-ORx Biosciences To Drive Healthcare Innovation In Africa

Sygen Pharmaceuticals Ltd, headquartered in Lagos, has partnered with ORx Pharmaceuticals Corporation, based in Ontario, Canada, to establish Sygen-ORx Biosciences.

This groundbreaking joint venture aims to revolutionise healthcare by addressing pharmaceutical drug security challenges through collaborative innovation.

ORx Pharmaceuticals, affiliated with the Toronto Institute of Pharmaceutical Technology—North America’s leading post-graduate institute for pharmaceutical technology and research—brings a wealth of expertise and patented technologies in drug development and commercialization to the table. With a history of delivering transformative therapies across various therapeutic areas, ORx has earned a reputation as a leader in the pharmaceutical industry, driven by a commitment to advancing medical science and improving patient care.

Sygen Pharmaceuticals, known for its pioneering spirit and dedication to scientific rigor, complements ORx’s strengths with its innovative approach to healthcare solutions. With a focus on developing high-quality medications and enhancing access to cutting-edge treatments, Sygen has become a trusted partner in driving positive change in Nigeria’s healthcare landscape.

The recent synergy between these two industry leaders is expected to accelerate the development and commercialisation of groundbreaking therapies, addressing unmet medical needs and improving healthcare access across the African continent and beyond.

Sygen-ORx Biosciences will focus on the development of improved formulations of generic pharmaceuticals, particularly products with established clinical efficacy that have already gained regulatory approval and achieved commercial success. Additionally, the joint venture will advance innovative drug discovery programs, aiming to bring these discoveries to both regional and global markets.

One of the key goals of Sygen-ORx Biosciences is to reduce costs and increase access to high-quality branded generic medicines across Africa. The joint venture will also leverage the expertise gained from global drug discovery, research, development, commercialisation, and distribution, with the aim of accelerating open innovation in early-stage drug discovery.

Dr. Alexander MacGregor, Chief Executive Officer (CEO) of ORx Pharmaceuticals, expressed his excitement about the collaboration: “Sygen-ORx Biosciences will build upon the foundation of excellence established by ORx and Sygen, ushering in a new era of healthcare innovation. With a shared commitment to scientific excellence and integrity, Sygen-ORx Biosciences is positioned to make a significant impact in the healthcare landscape, shaping the future of medicine for generations to come.”

Echoing this sentiment, Dr. Charles Ogunwuyi, CEO of Sygen Pharmaceuticals, stated: “Collaboration is at the heart of our mission at Sygen Pharmaceuticals, and we are excited to embark on this transformative journey with ORx Pharmaceuticals. Together, as Sygen-ORx, we have the opportunity to amplify our impact and drive innovation in healthcare, ultimately improving the lives of patients in Africa and beyond. Through our partnership with ORx Pharmaceuticals, we can leverage our collective strengths to deliver meaningful solutions that address critical medical challenges and advance patient care.”

With this joint venture, Sygen-ORx Biosciences is set to play a key role in shaping the future of healthcare, bringing innovative solutions to the forefront and ensuring that patients in Africa and around the world have access to the treatments they need.